Every Form 4 that Cytosorbents Corp. (CTSO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CTSO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTSO filings page.
Cytosorbents Corp (CTSO) reporting person Phillip P. Chan, Chief Executive Officer and director, purchased 3,774 shares of Common Stock in an open market transaction on September 15, 2026 at $6.00 per share, and now directly holds 100,996 shares of Common Stock, including restricted stock units.
The holdings include several tranches of RSUs that vest upon a "Change In Control" or over time under the company’s 2014 Long-Term Incentive Plan, as well as 83,782 shares of Common Stock. The share amounts reflect the 1-for-20 reverse stock split effected on September 8, 2026. No Rule 10b5-1 trading plan is reported.
Cytosorbents Corp (CTSO) reports that President and COO Vincent Capponi purchased Common Stock in open-market transactions on September 14, 2026, buying 1,800 shares at $6.07 per share and 273 shares at $5.90 per share, with no Rule 10b5-1 trading plan reported.
Capponi’s reported holdings include multiple tranches of RSUs that settle into Common Stock upon a Change in Control under the 2014 Long-Term Incentive Plan, time-based RSUs including 4,455 RSUs granted August 8, 2025 (2,228 unvested), and 25,736 shares of Common Stock owned, all figures reflecting the 1-for-20 reverse stock split effective September 8, 2026.
Cytosorbents Corp (CTSO) director Alan D. Sobel reported open-market purchases of company common stock on September 15, 2026. He bought a total of 2,500 shares in three transactions at prices between $6.01 and $6.12 per share. No Rule 10b5-1 trading plan is reported for these purchases. His equity interests also include restricted stock units that vest upon a Change in Control under the company’s 2014 Long-Term Incentive Plan and 6,422 shares of common stock owned directly, all reflecting a previously effected 1-for-20 reverse stock split.
Cytosorbents Corp (CTSO) reports that Chief Executive Officer and director Phillip P. Chan purchased 200,000 shares of Common Stock on September 4, 2026, in an open-market transaction at a weighted average price of $0.35 per share, with individual trades ranging from $0.3470 to $0.3599.
Following this purchase, Chan holds a reported total of 1,944,432 shares, consisting of Common Stock and restricted stock units that vest upon specified conditions, and the report notes that these amounts were not adjusted for a reverse stock split that occurred on September 8, 2026; no Rule 10b5-1 trading plan is reported.
Cytosorbents Corp Chief Financial Officer Peter J. Mariani reported an open-market purchase of 100,000 shares of Common Stock at a weighted average price of $0.44 per share on June 15, 2026. Following this transaction, he directly holds 638,113 shares, which include a mix of common shares and restricted stock units that vest over time or upon a defined change in control, subject to his continued service.
Cytosorbents Corp CEO Phillip P. Chan reported open-market purchases of company common stock. On June 12, 2026, he bought 251,136 shares at a weighted average price of $0.40 per share. On June 15, 2026, he bought another 10,333 shares at a weighted average price of $0.43 per share.
Following these transactions, Chan directly holds 1,744,432 shares reported as common stock, a figure that includes several grants of restricted stock units that vest upon a Change In Control or over time, plus 1,422,832 shares of currently owned common stock.
Cytosorbents Corp (CTSO) reported that its Chief Executive Officer and director, Phillip P. Chan, acquired additional company stock in an open market transaction. On 11/18/2025, he purchased 100,000 shares of Common Stock at a price of $0.64 per share. Following this transaction, he beneficially owns 1,482,963 shares, reflecting both directly owned shares and various restricted stock units (RSUs).
The footnotes explain that his holdings include multiple RSU grants that either vest upon a "Change In Control" under the company’s 2014 Long-Term Incentive Plan or in equal parts on the first and second anniversaries of their grant dates, subject to continued service. His position also includes 1,113,363 shares of Common Stock owned outright.